RecruitingNot ApplicableNCT04342429

Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer

RAD4649-19: Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer


Sponsor

Emory University

Enrollment

30 participants

Start Date

Mar 19, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining a specialized radiation therapy technique called intensity-modulated proton therapy (IMPT) in patients with small cell lung cancer. Proton therapy is a type of radiation that delivers energy more precisely to tumors and may cause fewer side effects than standard X-ray radiation. Researchers want to understand how well it works and what side effects it causes. **You may be eligible if:** - You have been diagnosed with small cell lung cancer (either limited or extensive stage) - Your doctor is recommending chest radiation using proton therapy - You are 18 years or older **You may NOT be eligible if:** - You have had prior radiation therapy that would overlap significantly with the new treatment area - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONProton-beam Therapy for Small Cell Lung Cancer

The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.


Locations(1)

Winship Cancer Institute

Atlanta, Georgia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04342429


Related Trials